U.S. Markets close in 3 hrs 55 mins

Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

Stock Research Monitor: SRRA, ONCE, and SPPI

LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 7,532.01, down 2.09%; the Dow Jones Industrial Average edged 1.33% lower, to finish at 24,252.80; and the S&P 500 closed at 2,717.07, down 1.37%. This Tuesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Sierra Oncology

On Monday, shares in Vancouver, Canada headquartered Sierra Oncology Inc. recorded a trading volume of 417,776 shares. The stock ended the session 1.52% lower at $3.25. The Company's shares have gained 40.09% in the last month, 51.16% over the previous three months, and 177.78% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 28.15% and 31.06%, respectively. Moreover, shares of Sierra Oncology , which researches, develops, and commercializes DNA Damage Response therapeutics for the treatment of patients with cancer in the US and internationally, have a Relative Strength Index (RSI) of 59.20. Get the full research report on SRRA for free by clicking below at:

www.wallstequities.com/registration/?symbol=SRRA


Sorrento Therapeutics

San Diego, California-based Sorrento Therapeutics Inc.'s stock closed the day 3.05% lower at $6.35 with a total trading volume of 2.57 million shares. The Company's shares have advanced 243.24% over the last twelve months. The stock is trading above its 200-day moving average by 23.44%. Additionally, shares of Sorrento Therapeutics, which engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide, have an RSI of 38.30. Access the free research report on SRNE now by signing up at:


www.wallstequities.com/registration/?symbol=SRNE


Spark Therapeutics

Shares in Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc. recorded a trading volume of 552,322 shares. The stock ended yesterday's trading session 3.83% lower at $86.63. The Company's shares have advanced 29.92% over the previous three months and 38.41% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 11.09% and 23.58%, respectively. Furthermore, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 60.70. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ONCE at:

www.wallstequities.com/registration/?symbol=ONCE


Spectrum Pharmaceuticals

Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc.'s stock finished Monday's session 1.81% lower at $18.98 with a total trading volume of 1.21 million shares. The Company's shares have advanced 157.18% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.06% and 5.13%, respectively. Additionally, shares of Spectrum Pharma, which develops and commercializes oncology and hematology drug products, have an RSI of 45.62. Aspiring Member, please take a moment to register below for your free research report on SPPI at:

www.wallstequities.com/registration/?symbol=SPPI

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities